IDEX Corporation (IEX) official guidance

Additionally, we are increasing our capital expenditures forecast from $90 million to approximately $110 million as we make select investments and capacity expansions to support our highest growth and high return businesses.

We are raising adjusted EBITDA margin expectations to a range of 27%-27.3%, up from 26.5%-27%.

Adjusted EBITDA margin is expected to be in the 26.5%-27% range in 2026, unchanged from our previous guidance.

Adjusted EBITDA margin is expected to be in the 26.5%-27% range in 2026.

Full year adjusted diluted EPS of $8.91 to $8.96, up approximately 12% year-over-year at midpoint, up from previous guidance of $8.70 to $8.85

Taken together, we are raising adjusted EPS guidance for 2026 from a range of $8.35-$8.55 to a range of $8.70-$8.85, representing high single-digit to low double-digit growth year-over-year.

•Full year adjusted diluted EPS of $8.70 to $8.85, up approximately 10% year-over-year at midpoint, up from previous guidance of $8.35 to $8.55

We are increasing our adjusted EPS guidance for 2026 by $0.20 to $8.35-$8.55, representing mid to high single-digit growth year-over-year.

Full year adjusted diluted EPS of $8.35 to $8.55, up from previous guidance of $8.15 to $8.35

Adjusted EPS guidance for 2026 is $8.15-$8.35, representing low to mid-single digit growth year-over-year.

Full year adjusted diluted EPS of $8.15 to $8.35

We continue to expect free cash flow conversion of at least 100% on an annual basis.

For the full year of 2026, we now expect organic growth in the 5%-6% range, an increase over our previous guidance of 3%-4% organic growth.

For the full year 2026, we now expect organic growth in the 3%-4% range, an increase over our original 1%-2% organic growth guidance coming into the year.

We plan on maintaining our quarterly repurchase level at around $75 million through the rest of 2026.

•Full year organic sales projected to increase 5% to 6% over the prior year, up from previous guidance of 3% to 4%

Full year organic sales projected to increase 3% to 4% over the prior year, up from previous guidance of 1% to 2%

For the full year 2026, we expect organic growth of 1%-2%.

Full year organic sales projected to increase 1% to 2% over the prior year

•Third quarter 2026 adjusted diluted EPS of $2.20 to $2.25

Our overall IDEX organic growth guidance balances approximate high single-digit growth for HST and flattish outlooks for FMT and FSDP.

Our overall IDEX organic growth guidance balances approximate mid-single digit growth for HST and flat to slightly down outlooks for FMT and FSDP, mirroring trends we experienced in the second half of 2025 and visibility afforded to us by HST's strong order book in the Q4.

Our overall IDEX organic growth guidance balances approximate high single-digit growth for HST and flattish outlooks for FMT and FSDP.

Our overall IDEX organic growth guidance balances approximate mid-single digit growth for HST and flat to slightly down outlooks for FMT and FSDP, mirroring trends we experienced in the second half of 2025 and visibility afforded to us by HST's strong order book in the Q4.

Our overall IDEX organic growth guidance balances approximate high single-digit growth for HST and flattish outlooks for FMT and FSDP.

Our overall IDEX organic growth guidance balances approximate mid-single digit growth for HST and flat to slightly down outlooks for FMT and FSDP, mirroring trends we experienced in the second half of 2025 and visibility afforded to us by HST's strong order book in the Q4.

Second quarter 2026 adjusted diluted EPS of $2.07 to $2.12

I think you should expect a similar level of activity that you saw in the second half of last year, which is around $75 million per quarter. That stepped up, as you mentioned, last year. The first part of last year was around $50 million a quarter, stepped it up to around $75 million in Q3 and Q4. I think that's probably the right assumption as you think about this next year.